Korean J Urol.  2009 Jul;50(7):642-648.

Plasma Insulin-Like Growth Factor-1 (IGF-1), IGF-Binding Protein-3, and the Risk of Prostate Cancer: A Matched Case-Control Study in a Korean Population

• Kim JH
• Park KJ
• Bae JB
• Yeo WG
• Byun SS
• Lee ES

Abstract

PURPOSE
Conflicting results have been reported for western populations on associations of serum insulin-like growth factor I (IGF-I) and major IGF-binding protein-3 (IGFBP-3) with the risk of prostate cancer. However, few data have been available for oriental populations. We undertook a matched case-control study in a low-risk Korean population to extend our knowledge about potential associations. MATERIALS AND METHODS: Serum IGF-I and IGFBP-3 levels were determined for 330 men (165 cases and 165 healthy age-matched controls). Conditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between plasma IGF levels and prostate cancer. We also investigated the potential influence of the associations according to clinical risk for advanced disease at diagnosis. RESULTS: We noted that the risks of prostate cancer were unrelated to the IGF-1 level and IGF-I/IGFBP-3 molar ratio. In contrast, a strong inverse association was observed between IGFBP-3 levels and the risk for prostate cancer. Men in the highest quartile of IGFBP-3 levels had a 71% reduced risk of prostate cancer compared with men in the lowest quartile (OR=0.29, 95% CI: 0.11-0.64, P(trend)<0.001). Subgroup analysis revealed a significant inverse association between plasma IGFBP-3 and the likelihood of a high risk prostate cancer. CONCLUSIONS: Plasma IGFBP-3 levels were inversely associated with the risk of prostate cancer and the likelihood for high-risk disease, suggesting that IGFBP-3 plays a protective role against prostate cancer in the Korean population.

Keyword

Prostatic neoplasms; Insulin-like growth factor I; Insulin-like growth factor binding protein 3

MeSH Terms

Case-Control Studies
Humans
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Logistic Models
Male
Molar
Odds Ratio
Plasma
Prostate
Prostatic Neoplasms
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I

Reference

1.Fürstenberger G., Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002. 3:298–302.

2.Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer. 1992. 65:311–20.

3.Chan JM., Stampfer MJ., Giovannucci E., Gann PH., Ma J., Wilkinson P, et al. Plasmainsulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998. 79:63–6.

4.Mantzoros CS., Tzonou A., Signorello LB., Stampfer M., Trichopoulos D., Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997. 76:1115–8.

5.Leal SM., Liu Q., Huang SS., Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997. 72:20572–6.

6.Schedlich LJ., Le Page SL., Firth SM., Briggs LJ., Jans DA., Baxter RC. Nuclear import of insulin-like growth factor-inding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem. 2000. 275:23462–70.

7.Liu B., Lee HY., Weinzimer SA., Powell DR., Clifford JL., Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000. 275:33607–13.

8.Boyle BJ., Zhao XY., Cohen P., Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha, 25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 2001. 165:1319–24.

9.Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995. 377:646–9.

10.Chokkalingam AP., Pollak M., Fillmore CM., Gao YT., Stanczyk FZ., Deng J, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2001. 10:421–7.

11.Stattin P., Bylund A., Rinaldi S., Biessy C., Déchaud H., Stenman UH, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000. 92:1910–7.

12.Harman SM., Metter EJ., Blackman MR., Landis PK., Carter HB. Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 2000. 85:4258–65.

13.Wolk A., Mantzoros CS., Andersson SO., Bergström R., Signorello LB., Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998. 90:911–5.

14.Severi G., Morris HA., MacInnis RJ., English DR., Tilley WD., Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006. 15:1137–41.

15.Chen C., Lewis SK., Voigt L., Fitzpatrick A., Plymate SR., Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 2005. 103:76–84.

16.Renehan AG., Zwahlen M., Minder C., O'Dwyer ST., Shalet SM., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363:1346–53.

17.D'Amico AV., Whittington R., Malkowicz SB., Schultz D., Blank K., Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998. 280:969–74.

18.Wang L., Habuchi T., Tsuchiya N., Mitsumori K., Ohyama C., Sato K, et al. Insulin-like growth factor-binding protein-3 gene −202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 2003. 63:4407–11.

19.Moon JW., Chang YS., Ahn CW., Yoo KN., Shin JH., Kong JH, et al. Promoter −202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer. 2006. 118:353–6.

20.Shariat SF., Lamb DJ., Kattan MW., Nguyen C., Kim J., Beck J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002. 20:833–41.

21.Kim YJ., Chang IH., Gil MC., Hong SK., Byun SS., Lee SE. Concordance of Gleason scores between prostate needle biopsy and radical prostatectomy specimens according to the number of biopsy cores. Korean J Urol. 2006. 47:482–8.

22.Chung JS., Han BK., Jeong SJ., Hong SK., Byun SS., Choe G, et al. Pathologic outcome of unilateral low risk prostate cancers on multicore prostate biopsy after radical prostatectomy. Korean J Urol. 2008. 49:874–8.

23.Yu H., Mistry J., Nicar MJ., Khosravi MJ., Diamandis A., van Doorn J, et al. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. Clin Lab Anal. 1999. 13:166–72.

24.Goodman-Gruen D., Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol. 1997. 145:970–6.